Statistical excellence in the pharmaceutical industry

Our award for statistical excellence in the pharmaceutical industry is made jointly with the PSI (Statisticians in the Pharmaceutical Industry) every year.

The award is for the most influential example of the application of an existing statistical practice, or the implementation of an innovative statistical practice, in this industry.


We look for entries that have demonstrated one or more of the following:

- A clear understanding of the needs of researchers and investigators
- An application of an existing statistical practice to a new area that has increased the quality and efficiency of investigations
- A new development in the design of investigations and/or the analysis of data that has led to further insights into the safety, efficacy and value of medicines or devices
- An excellent way to communicate results that is clear and helpful to a wide array of users, showing how statisticians understand the range of user needs

The deadline for entries for this year’s awards has now passed. Award winners will be notified by the end of April 2017 and the awards ceremony will take place at the PSI Conference, held in London 14th - 17th of May 2017.

Previous winners

The 2016 award was won by Richard Nixon of Novartis, and he was presented with his award at the PSI Conference in May 2016. Read more about his winning entry on StatsLife.

Katrina Gore and Nicky Best (joint winners, 2015, Pfizer and GSK respectively). Katrina Gore for her work on the Assay Capability Tool (ACT), designed to guide the development of drug discovery assays. Nicky Best for her work implementing a process that has turned beliefs about the chances of success into formal prior distributions. Read more about the winning entries on StatsLife.
Craig Mallinckrodt (2014, Eli Lilly & Company) for his book, Preventing and Treating Missing Data in Longitudinal Clinical Trials. Download RSS Statistical Excellence Award Winners 2014 (PDF).

Björn Bornkamp (2013, Novartis) for ‘Developing efficient statistical methodology and software for model-based design and analysis of Phase II dose-finding studies under model uncertainty’

Harry Southworth (2012, AstraZeneca) for ‘Producing a method of evaluating clinical laboratory safety data using extreme value modelling’

Phil Woodward (2011, Pfizer) for ‘A portfolio-wide implementation of a Bayesian framework for early clinical development within a major pharmaceutical company’